{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:32:54Z","timestamp":1774693974304,"version":"3.50.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hematopoietic cell transplantation (HCT) remains a cornerstone of treatment of many hematologic malignancies but transplant-associated morbidity and mortality limit application to older patients. Biologic or chronologic age barriers to HCT have fallen, because patients in their 8th decade of life comprise the group with the greatest rise in transplant use over the past decade. Evaluating physiologic age or general health in older transplant candidates requires a systematic approach inclusive of functional and comorbidity assessment, which typically is accomplished through geriatric assessment (GA). GA incorporates measures of comorbidity, function, nutrition, social support, and other health-related domains to better describe physiologic age. Older allogeneic transplant patients have a surprisingly high prevalence of vulnerabilities by GA prior to transplant, and significant comorbidity or functional limitations heighten the risks of transplant-related mortality. Ultimately, incorporation of physiologic age can improve estimates of nondisease life expectancy, prognostic survival after HCT, and inform HCT candidacy. Future research on the optimal tools to characterize physiologic age and appropriate interventions in the context of transplant are needed.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.99","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"99-105","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Biologic vs physiologic age in the transplant candidate"],"prefix":"10.1182","volume":"2016","author":[{"given":"Andrew S.","family":"Artz","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111706513815600_B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, cellular senescence, and cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu Rev Physiol"},{"issue":"36","key":"2019111706513815600_B2","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mr\u00f3zek","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111706513815600_B3","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du My\u00e9lome experience","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111706513815600_B4","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111706513815600_B5","article-title":"Current uses and outcomes of hematopoietic stem cell transplantation","volume-title":"2014 CIBMTR summary slides. Minneapolis","author":"Pasquini","year":"2015"},{"issue":"3","key":"2019111706513815600_B6","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.bbmt.2015.11.360","article-title":"Increasing use of allogeneic hematopoietic cell transplantation (HCT) in patients age 70 years and older: a CIBMTR study of trends and outcomes","volume":"22","author":"Muffly","year":"2016","journal-title":"Biology of Blood and Marrow Transplant"},{"issue":"2","key":"2019111706513815600_B7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2014.255","article-title":"Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years","volume":"50","author":"Auner","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111706513815600_B8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2019111706513815600_B9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bbmt.2013.06.014","article-title":"Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States","volume":"19","author":"Yao","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111706513815600_B10","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111706513815600_B11","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"issue":"7","key":"2019111706513815600_B12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","article-title":"Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?","volume":"29","author":"Horan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111706513815600_B13","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3324\/haematol.13273","article-title":"Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry","volume":"93","author":"Jantunen","year":"2008","journal-title":"Haematologica"},{"issue":"35","key":"2019111706513815600_B14","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","article-title":"Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111706513815600_B15","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"10","key":"2019111706513815600_B16","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3026(15)00148-9","article-title":"Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis","volume":"2","author":"Versluis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"8","key":"2019111706513815600_B17","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111706513815600_B18","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","article-title":"Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research Study","volume":"21","author":"Sorror","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"29","key":"2019111706513815600_B19","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111706513815600_B20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"issue":"9","key":"2019111706513815600_B21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jama.2013.1184","article-title":"Predicting 10-year mortality for older adults","volume":"309","author":"Cruz","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"2019111706513815600_B22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1634\/theoncologist.2015-0200","article-title":"Prognostic importance of pretransplant functional capacity after allogeneic hematopoietic cell transplantation","volume":"20","author":"Jones","year":"2015","journal-title":"Oncologist"},{"issue":"24","key":"2019111706513815600_B23","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111706513815600_B24","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults","volume":"63","author":"By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"2019111706513815600_B25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbmt.2012.11.006","article-title":"Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients","volume":"19","author":"Muffly","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111706513815600_B26","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.2105\/AJPH.2011.300602","article-title":"Trends in US older adult disability: exploring age, period, and cohort effects","volume":"102","author":"Lin","year":"2012","journal-title":"Am J Public Health"},{"issue":"4","key":"2019111706513815600_B27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jgo.2014.04.004","article-title":"Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates","volume":"5","author":"Holmes","year":"2014","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"2019111706513815600_B28","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.bbmt.2013.12.075","article-title":"Comprehensive geriatric assessment identifies significant functional impairments in older hematopoietic cell transplant recipients","volume":"20","author":"Olin","year":"2014","journal-title":"Biology of Blood and Marrow Transplant"},{"issue":"4","key":"2019111706513815600_B29","doi-asserted-by":"crossref","first-page":"e61586","DOI":"10.1371\/journal.pone.0061586","article-title":"The influence of social support on hematopoietic stem cell transplantation survival: a systematic review of literature","volume":"8","author":"Beattie","year":"2013","journal-title":"PLoS One"},{"issue":"20","key":"2019111706513815600_B30","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","article-title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","volume":"115","author":"Pavl\u016f","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111706513815600_B31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbmt.2008.08.004","article-title":"Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation","volume":"14","author":"Artz","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111706513815600_B32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jama.2015.7","article-title":"Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia","volume":"313","author":"Gadalla","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"2019111706513815600_B33","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/bmt.2015.143","article-title":"Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma","volume":"50","author":"Rosko","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111706513815600_B34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111706513815600_B35","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00432-006-0115-7","article-title":"Impairment in functional status and survival in patients with acute myeloid leukaemia","volume":"132","author":"Wedding","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"2019111706513815600_B36","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111706513815600_B37","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111706513815600_B38","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.bbmt.2014.05.027","article-title":"Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902","volume":"20","author":"Jacobsen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111706513815600_B39","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/j.1532-5415.2012.04214.x","article-title":"Challenges in synthesizing and interpreting the evidence from a systematic review of multifactorial interventions to prevent functional decline in older adults","volume":"60","author":"Lin","year":"2012","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2019111706513815600_B40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/bmt.2015.241","article-title":"Process of allogeneic hematopoietic cell transplantation decision making for older adults","volume":"51","author":"Randall","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/99\/1250550\/hem088370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/99\/1250550\/hem088370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T11:51:53Z","timestamp":1573991513000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/99\/21066\/Biologic-vs-physiologic-age-in-the-transplant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.99","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}